Abivax SA (ABVX) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.118x

Based on the latest financial reports, Abivax SA (ABVX) has a cash flow conversion efficiency ratio of -0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-50.52 Million ≈ $-59.06 Million USD) by net assets (€429.59 Million ≈ $502.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ABVX market cap overview for the company's overall valuation and market capitalisation.

Abivax SA - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Abivax SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Abivax SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Abivax SA ranked by their cash flow conversion efficiency. See Abivax SA (ABVX) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Suzhou Everbright Photonics Co. Ltd. A SHG:688048	-0.001x
Henan Shenhuo Coal & Power Co Ltd SHE:000933	0.057x
SpareBank 1 Sør-Norge ASA OL:SB1NO	-0.060x
Westlake Chemical Corporation NYSE:WLK	0.035x
Campbell’s Co NYSE:CPB	0.069x
Gildan Activewear Inc. TO:GIL	-0.081x
Skyworks Solutions Inc NASDAQ:SWKS	0.009x
Brenntag SE F:BNR	-0.010x

Annual Cash Flow Conversion Efficiency for Abivax SA (2013–2025)

The table below shows the annual cash flow conversion efficiency of Abivax SA from 2013 to 2025. View ABVX stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€455.20 Million ≈ $532.18 Million	€-162.09 Million ≈ $-189.50 Million	-0.356x	+90.62%
2024-12-31	€40.58 Million ≈ $47.45 Million	€-154.07 Million ≈ $-180.13 Million	-3.796x	-666.11%
2023-12-31	€196.01 Million ≈ $229.16 Million	€-97.13 Million ≈ $-113.56 Million	-0.496x	+98.58%
2022-12-31	€1.88 Million ≈ $2.20 Million	€-65.58 Million ≈ $-76.67 Million	-34.845x	-2096.03%
2021-12-31	€28.77 Million ≈ $33.64 Million	€-45.66 Million ≈ $-53.38 Million	-1.587x	+75.14%
2020-12-31	€4.67 Million ≈ $5.46 Million	€-29.82 Million ≈ $-34.87 Million	-6.382x	-173.67%
2019-12-31	€11.78 Million ≈ $13.77 Million	€-27.47 Million ≈ $-32.12 Million	-2.332x	-453.39%
2018-12-31	€34.65 Million ≈ $40.51 Million	€-14.60 Million ≈ $-17.07 Million	-0.421x	-140.30%
2017-12-31	€48.18 Million ≈ $56.33 Million	€-8.45 Million ≈ $-9.88 Million	-0.175x	+36.28%
2016-12-31	€56.72 Million ≈ $66.31 Million	€-15.61 Million ≈ $-18.25 Million	-0.275x	-32.46%
2015-12-31	€71.74 Million ≈ $83.87 Million	€-14.90 Million ≈ $-17.42 Million	-0.208x	-113.32%
2014-12-31	€33.94 Million ≈ $39.67 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	-0.25%
2013-12-31	€34.02 Million ≈ $39.77 Million	€-3.31 Million ≈ $-3.86 Million	-0.097x	--

About Abivax SA

PA:ABVX France Biotechnology

Market Cap

$9.28 Billion

€7.94 Billion EUR

Market Cap Rank

#2478 Global

#50 in France

Share Price

€91.00

Change (1 day)

-2.88%

52-Week Range

€63.10 - €135.00

All Time High

€135.00